BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

Abstract

4Sorbonne Université, Paris, France; 5Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France; 6Escola de Medicina e Saúde Pública, Salvador Bahia, Brazil; 7University of Miami Miller School of Medicine, Miami, USA; 8Organizacion Medica de Investigacion, Buenos Aires, Argentina; 9Tuen Mun Hospital, Hong Kong SAR, China; 10NYU School of Medicine, New York City, USA; 11The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 12Leiden University Medical Center, Leiden, The Netherlands; 13GlaxoSmithKline, Uxbridge, UK; 14GlaxoSmithKline, Collegeville, USA; 15Parexel, Durham, USA Richard Furie1, Brad H Rovin2, Frédéric Houssiau3, Zahir Amoura4,5, Mittermayer B Santiago6, Gabriel Contreras7, Ana Malvar8, Chi Chiu Mok9, Amit Saxena10, Xueqing Yu11, Y K Onno Teng12, Carly Barnett13, Susan W Burriss14, Yulia Green13, Beulah Ji13, Christi Kleoudis15, David Roth14 BLISS-LN: A randomised, double-blind,